Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GUTS 
Fractyl Health, Inc. Common Stock (GUTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: GUTS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.44
1 Year Target Price $7.44
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.62% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 213.79M USD | Price to earnings Ratio - | 1Y Target Price 7.44 |
Price to earnings Ratio - | 1Y Target Price 7.44 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 0.82 - 3.03 | Updated Date 12/2/2025 |
52 Weeks Range 0.82 - 3.03 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.32 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.42 | Actual -0.71 |
Profitability
Profit Margin - | Operating Margin (TTM) -3291400% |
Management Effectiveness
Return on Assets (TTM) -51.17% | Return on Equity (TTM) -518.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 199686770 | Price to Sales(TTM) 71263.11 |
Enterprise Value 199686770 | Price to Sales(TTM) 71263.11 | ||
Enterprise Value to Revenue 66562.26 | Enterprise Value to EBITDA - | Shares Outstanding 137044440 | Shares Floating 111337644 |
Shares Outstanding 137044440 | Shares Floating 111337644 | ||
Percent Insiders 1.73 | Percent Institutions 74.38 |
Upturn AI SWOT
Fractyl Health, Inc. Common Stock
Company Overview
History and Background
Fractyl Health, Inc. is a metabolic therapeutics company dedicated to developing innovative treatments for type 2 diabetes (T2D) and obesity. It was founded to address the root causes of metabolic disease, aiming to improve patient outcomes through targeted interventions.
Core Business Areas
- Revita DMR System: Fractyl Health's primary focus is on the Revita DMR (Duodenal Mucosal Resurfacing) system. This is a minimally invasive endoscopic procedure designed to regenerate the lining of the duodenum, aiming to improve insulin sensitivity and glycemic control in T2D patients.
- ReVITA T2D Pivotal Trial: Fractyl Health is currently involved in a pivotal clinical trial, ReVITA T2D, to evaluate the safety and efficacy of Revita DMR in a larger patient population, paving the way for potential regulatory approval.
Leadership and Structure
Fractyl Health is led by a team of experienced executives and scientists in the fields of gastroenterology, metabolic disease, and medical device development. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Revita DMR System: The Revita DMR system is Fractyl Health's flagship product. While specific market share data is not publicly available due to the innovative nature of the technology and its stage of development (clinical trials), it aims to compete with existing diabetes management methods like medication and bariatric surgery. Competitors include pharmaceutical companies producing diabetes drugs (e.g., Novo Nordisk, Eli Lilly) and companies offering bariatric surgery solutions.
Market Dynamics
Industry Overview
The metabolic disease treatment market, particularly for type 2 diabetes and obesity, is large and growing due to the increasing prevalence of these conditions globally. The industry includes pharmaceuticals, medical devices, and surgical interventions.
Positioning
Fractyl Health positions itself as an innovator in metabolic therapeutics, offering a potentially disease-modifying treatment for T2D. Its competitive advantage lies in its unique approach to addressing the root cause of metabolic dysfunction in the duodenum.
Total Addressable Market (TAM)
The TAM for T2D and obesity treatments is estimated to be in the hundreds of billions of dollars globally. Fractyl Health, with its Revita DMR system, aims to capture a significant portion of this market by offering a novel and potentially more effective treatment option.
Upturn SWOT Analysis
Strengths
- Novel technology with potential for disease modification
- Strong intellectual property position
- Experienced leadership team
- Targeting a large and growing market
Weaknesses
- Limited clinical data to date
- High dependence on successful clinical trial outcomes
- Regulatory approval uncertainty
- Commercialization challenges for a new technology
Opportunities
- Positive clinical trial results leading to regulatory approval
- Expansion into new geographic markets
- Partnerships with pharmaceutical companies and healthcare providers
- Development of new applications for Revita DMR technology
Threats
- Competition from established diabetes treatments
- Adverse clinical trial results
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- LLY
- NVO
- BMRA
Competitive Landscape
Fractyl Health's advantage is its novel, minimally invasive approach. Disadvantages include being a smaller company competing with established pharmaceutical giants with extensive resources and market presence.
Growth Trajectory and Initiatives
Historical Growth: Fractyl Health's historical growth is reflected in its progress through clinical trials and the development of its Revita DMR system.
Future Projections: Future growth is dependent on successful completion of the ReVITA T2D trial and subsequent regulatory approval. Analyst estimates vary based on perceived probability of success and market adoption rates.
Recent Initiatives: Recent initiatives include enrolling patients in the ReVITA T2D trial and securing additional funding to support clinical development.
Summary
Fractyl Health is an innovative company with a novel technology to treat T2D and obesity. Its potential for disease modification presents a strong opportunity, but its success hinges on positive clinical trial results and regulatory approval. The company faces competition from established players in the diabetes market and must navigate the challenges of commercializing a new technology. Its cash burn rate and ongoing funding requirements also need to be monitored.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are based on approximations and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fractyl Health, Inc. Common Stock
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2024-02-02 | Co-Founder, CEO & Director Dr. Harith Rajagopalan M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 101 | Website https://fractyl.com |
Full time employees 101 | Website https://fractyl.com | ||
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.